Panbela Therapeutics (NASDAQ: PBLA) is one of 865 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Panbela Therapeutics to similar businesses based on the strength of its institutional ownership, earnings, analyst recommendations, valuation, dividends, profitability and risk.
Earnings & Valuation
This table compares Panbela Therapeutics and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Panbela Therapeutics||N/A||-$4.77 million||-4.23|
|Panbela Therapeutics Competitors||$1.71 billion||$122.54 million||-2.44|
Institutional and Insider Ownership
6.9% of Panbela Therapeutics shares are owned by institutional investors. Comparatively, 46.0% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 20.3% of Panbela Therapeutics shares are owned by company insiders. Comparatively, 14.7% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Panbela Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Panbela Therapeutics Competitors||-2,680.16%||-112.45%||-27.44%|
This is a summary of current ratings and price targets for Panbela Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Panbela Therapeutics Competitors||4768||17996||39488||770||2.58|
Panbela Therapeutics presently has a consensus target price of $9.00, suggesting a potential upside of 243.51%. As a group, “Pharmaceutical preparations” companies have a potential upside of 55.16%. Given Panbela Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Panbela Therapeutics is more favorable than its rivals.
Panbela Therapeutics beats its rivals on 7 of the 12 factors compared.
About Panbela Therapeutics
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.